Roginolisib

4 trials 3 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

1 Completed trials

2 Sponsors

4 Countries

Phase II

Phase I/II

Phase II: 1 Phase I/II: 3

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 1 Uveal melanoma 1 Ocular melanoma 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

iOnctura SA 3 LYSARC 1

All trials

4 total

PLATFORM - A PLATFORM TRIAL, EVALUATING NEW DRUGS OR COMBINATION IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMAS Recruiting

2024-514954-63-00 Phase I/II 1 country LYSARC
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II 2 countries iOnctura SA
Phase II study of Roginolisib in UM patients Recruiting

2024-514333-37-00 Phase II 2 countries iOnctura SA
A Phase I/IIa Study of Roginolisib in combination with dostarlimab with or without docetaxel in Advanced NSCLC (PULMO-01) Ended

2024-517741-14-00 Phase I/II 3 countries iOnctura SA

Showing 1–4 of 4 trials

← All drugs A–Z